{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:12:37Z","timestamp":1792069957789,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Stockholm Cancer Society"},{"name":"King Gustav V Jubilee Fund"},{"DOI":"10.13039\/501100004348","name":"Stockholm County Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.1016\/j.ejca.2012.07.003","type":"journal-article","created":{"date-parts":[[2012,8,11]],"date-time":"2012-08-11T16:36:29Z","timestamp":1344702989000},"page":"52-59","source":"Crossref","is-referenced-by-count":145,"title":["Hormone replacement therapy after breast cancer: 10 year follow up of the Stockholm randomised trial"],"prefix":"10.1016","volume":"49","author":[{"given":"Mia","family":"Fahl\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Fornander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemming","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars-Erik","family":"Rutqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"von Schoultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2012.07.003_b0005","unstructured":"The National Board of Health and Welfare, Cancer Incidence in Sweden. Statistics \u2013 health and diseases. <http:\/\/www.socialstyrelsen.se\/>; 2009."},{"key":"10.1016\/j.ejca.2012.07.003_b0010","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S1470-2045(05)70316-8","article-title":"Management of menopausal symptoms in patients with breast cancer: an evidence-based approach","volume":"6","author":"Hickey","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.07.003_b0015","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)15493-7","article-title":"HABITS (hormonal replacement therapy after breast cancer \u2013 is it safe?), a randomised comparison: trial stopped","volume":"363","author":"Holmberg","year":"2004","journal-title":"The Lancet"},{"key":"10.1016\/j.ejca.2012.07.003_b0020","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jnci\/dji071","article-title":"Menopausal hormone therapy after breast cancer: The Stockholm randomized trial","volume":"97","author":"von Schoultz","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.07.003_b0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jnci\/djn058","article-title":"Increased risk of recurrence after hormone replacement therapy in breast cancer survivors","volume":"100","author":"Holmberg","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.07.003_b0030","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up","volume":"359","author":"Clark","year":"2002","journal-title":"The Lancet"},{"key":"10.1016\/j.ejca.2012.07.003_b0035","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2307\/2530374","article-title":"The analysis of failure times in the presence of competing risks","volume":"34","author":"Prentice","year":"1978","journal-title":"Biometrics"},{"key":"10.1016\/j.ejca.2012.07.003_b0040","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00000421-200012000-00001","article-title":"Breast cancer survival and hormone replacement therapy: a cohort analysis","volume":"23","author":"DiSaia","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.003_b0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1196\/annals.1365.032","article-title":"Hormone replacement therapy in breast cancer survivors","volume":"1092","author":"Xydakis","year":"2006","journal-title":"Ann NY Acad Sci"},{"key":"10.1016\/j.ejca.2012.07.003_b0050","doi-asserted-by":"crossref","first-page":"R535","DOI":"10.1186\/bcr1035","article-title":"Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence","volume":"7","author":"Col","year":"2005","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2012.07.003_b0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.maturitas.2005.03.004","article-title":"Menopausal hormone therapy (HT) in patients with breast cancer","volume":"53","author":"Batur","year":"2006","journal-title":"Maturitas"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2012.07.003_b0060","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1210\/jc.2009-2509","article-title":"Postmenopausal hormone therapy: an Endocrine Society Scientific Statement","volume":"95","author":"Santen","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejca.2012.07.003_b0065","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(08)70341-3","article-title":"Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised non-inferiority trial","volume":"10","author":"Kenemans","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2012.07.003_b0070","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1200\/JCO.2008.21.6432","article-title":"Estrogen-progestogen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risk?","volume":"27","author":"Fournier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.003_b0075","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1093\/jnci\/djq527","article-title":"Breast cancer risk in relation to the interval between menopause and starting hormone therapy","volume":"103","author":"Beral","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.07.003_b0080","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10495-005-1903-2","article-title":"Down-regulation of Bcl-2 enhances estrogen apoptotic action in long-term estradiol-depleted ER(+) breast cancer cells","volume":"10","author":"Song","year":"2005","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejca.2012.07.003_b0085","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/jnci\/dji400","article-title":"Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation","volume":"97","author":"Lewis","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.07.003_b0090","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1001\/jama.283.4.485","article-title":"Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk","volume":"283","author":"Schairer","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.ejca.2012.07.003_b0095","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/humupd\/dmi028","article-title":"Breast cancer risk with postmenopausal hormone treatment","volume":"11","author":"Collins","year":"2005","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejca.2012.07.003_b0100","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1093\/aje\/kwn090","article-title":"Conjugated equine estrogens and breast cancer risk in the Women\u2019s Health Initiative clinical trial and observational study","volume":"167","author":"Prentice","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ejca.2012.07.003_b0105","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/GRF.0b013e318180b8ed","article-title":"Breast cancer and hormonal therapy","volume":"51","author":"Conner","year":"2008","journal-title":"Clin Obstet Gynecol"},{"key":"10.1016\/j.ejca.2012.07.003_b0110","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/jnci\/88.21.1543","article-title":"Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early-stage breast cancer","volume":"88","author":"Swedish Breast Cancer Cooperative Group","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2012.07.003_b0140","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: an overview of the randomized trials","volume":"351","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2012.07.003_b0120","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s10549-008-0284-y","article-title":"The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer","volume":"116","author":"Osborne","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejca.2012.07.003_b0125","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1200\/JCO.2005.04.3745","article-title":"Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms","volume":"24","author":"Sestak","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2012.07.003_b0145","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3109\/13697131003660593","article-title":"Health-related quality of life during hormone therapy after breast cancer: a randomized trial","volume":"14","author":"Fahl\u00e9n","year":"2011","journal-title":"Climacteric"},{"key":"10.1016\/j.ejca.2012.07.003_b0135","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0015-0282(99)00510-5","article-title":"Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?","volume":"73","author":"Marsden","year":"2000","journal-title":"Fertil Steril"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912005497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804912005497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T14:27:30Z","timestamp":1542810450000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804912005497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S0959804912005497"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2012.07.003","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]}}}